IL318381A - Methods of tricyclic akr1c3 dependent kars inhibitor dosing field of the invention - Google Patents
Methods of tricyclic akr1c3 dependent kars inhibitor dosing field of the inventionInfo
- Publication number
- IL318381A IL318381A IL318381A IL31838125A IL318381A IL 318381 A IL318381 A IL 318381A IL 318381 A IL318381 A IL 318381A IL 31838125 A IL31838125 A IL 31838125A IL 318381 A IL318381 A IL 318381A
- Authority
- IL
- Israel
- Prior art keywords
- kars
- tricyclic
- methods
- inhibitor dosing
- akr1c3
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263369399P | 2022-07-26 | 2022-07-26 | |
| PCT/IB2023/057314 WO2024023641A1 (en) | 2022-07-26 | 2023-07-18 | Methods of tricyclic akr1c3 dependent kars inhibitor dosing field of the invention |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318381A true IL318381A (en) | 2025-03-01 |
Family
ID=87555041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318381A IL318381A (en) | 2022-07-26 | 2023-07-18 | Methods of tricyclic akr1c3 dependent kars inhibitor dosing field of the invention |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20260007654A1 (en) |
| EP (1) | EP4561702A1 (en) |
| JP (1) | JP2025526359A (en) |
| KR (1) | KR20250040691A (en) |
| CN (1) | CN119486737A (en) |
| AU (1) | AU2023314349A1 (en) |
| CA (1) | CA3258544A1 (en) |
| IL (1) | IL318381A (en) |
| MX (1) | MX2025000969A (en) |
| TW (1) | TW202404589A (en) |
| WO (1) | WO2024023641A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| WO2016145092A1 (en) | 2015-03-10 | 2016-09-15 | Threshold Pharmaceuticals, Inc. | Dna alkylating agents |
| UY38806A (en) | 2019-08-01 | 2021-02-26 | Novartis Ag | AKR1C3-DEPENDENT KARS TRICYCLIC INHIBITOR COMPOUNDS, COMPOSITIONS AND THEIR USES |
| IL300833A (en) * | 2020-09-02 | 2023-04-01 | Ascentawits Pharmaceuticals Ltd | Akr1c3 detection method, and diagnostic kit for detecting akr1c3 and use thereof |
-
2023
- 2023-07-18 US US18/993,107 patent/US20260007654A1/en active Pending
- 2023-07-18 CN CN202380048466.6A patent/CN119486737A/en active Pending
- 2023-07-18 JP JP2025503353A patent/JP2025526359A/en active Pending
- 2023-07-18 EP EP23750746.2A patent/EP4561702A1/en active Pending
- 2023-07-18 KR KR1020257005398A patent/KR20250040691A/en active Pending
- 2023-07-18 WO PCT/IB2023/057314 patent/WO2024023641A1/en not_active Ceased
- 2023-07-18 CA CA3258544A patent/CA3258544A1/en active Pending
- 2023-07-18 AU AU2023314349A patent/AU2023314349A1/en active Pending
- 2023-07-18 IL IL318381A patent/IL318381A/en unknown
- 2023-07-24 TW TW112127475A patent/TW202404589A/en unknown
-
2025
- 2025-01-23 MX MX2025000969A patent/MX2025000969A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119486737A (en) | 2025-02-18 |
| TW202404589A (en) | 2024-02-01 |
| AU2023314349A1 (en) | 2024-11-21 |
| EP4561702A1 (en) | 2025-06-04 |
| US20260007654A1 (en) | 2026-01-08 |
| MX2025000969A (en) | 2025-03-07 |
| JP2025526359A (en) | 2025-08-13 |
| CA3258544A1 (en) | 2024-02-01 |
| WO2024023641A1 (en) | 2024-02-01 |
| KR20250040691A (en) | 2025-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287792A (en) | Tricyclic akr1c3 dependent kars inhibitors | |
| IL291933A (en) | Compositions of oligonucleotides and methods of using them | |
| ZA202205938B (en) | Small molecule inhibitors of kras g12c mutant | |
| SG11202104927QA (en) | Improved synthesis of key intermediate of kras g12c inhibitor compound | |
| EP3856742C0 (en) | TRICYCLIC JANUS KINASE-1 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | |
| DK3442973T3 (en) | PREVIOUSLY UNKNOWN COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME | |
| IL308476A (en) | Inhibitors of the menin-mll interaction | |
| IT201600104717A1 (en) | TENSIOACTIVE COMPOSITIONS FOR THE TREATMENT OF UNDERGROUND FORMATIONS AND OIL PRODUCTS | |
| IL288387A (en) | Small molecule inhibitors of nf-kb inducing kinase | |
| EP3748653C0 (en) | DC BASIN INSULATOR | |
| MA50250A (en) | TETRAHYDROIMIDAZO QUINOLEIN COMPOSITIONS USED AS CBP / P300 INHIBITORS | |
| SG11202104192TA (en) | Combination of small molecule cd-47 inhibitors with other anti-cancer agents | |
| DK3816247T3 (en) | HARDENING MIXTURE | |
| EP4003986A4 (en) | INHIBITOR COMPOUNDS | |
| EP3402521A4 (en) | INHIBITION OF ALLERGIC REACTION USING IL-33 INHIBITOR | |
| SG11202008925VA (en) | Inhibitors of micro-rna 22 | |
| ZA202110347B (en) | Bicyclic compound as rip-1 kinase inhibitor and application thereof | |
| IL290324A (en) | Compositions of trofinetide | |
| GB201905328D0 (en) | Inhibitor compounds | |
| IL284343A (en) | Equipment for aiding the traceability of agri-food products | |
| HK40120424A (en) | Methods of tricyclic akr1c3 dependent kars inhibitor dosing field of the invention | |
| CY1124258T1 (en) | COMPOUNDS USEFUL FOR INHIBITING ROR-γ-t | |
| DK4013756T3 (en) | MLL1 inhibitors and anticancer agents | |
| DK3595442T3 (en) | MICROCAPE-LEADED NITRIFICATION INHIBITOR COMPOSITIONS | |
| CA3258544A1 (en) | Methods of tricyclic akr1c3 dependent kars inhibitor dosing |